BioArctic AB and its partner Eisai has presented new findings on lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
